Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic.

Aged Alzheimer Disease / diagnosis Biomarkers Case-Control Studies Cognitive Dysfunction / diagnosis Female Humans Macula Lutea / diagnostic imaging Male Tomography, Optical Coherence

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
31 01 2020
Historique:
received: 22 09 2019
accepted: 10 01 2020
entrez: 2 2 2020
pubmed: 2 2 2020
medline: 18 11 2020
Statut: epublish

Résumé

Building on previous studies that report thinning of the macula in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients, the use of optical coherence tomography (OCT) has been proposed as a potential biomarker for AD. However, other studies contradict these results. A total of 930 participants (414 cognitively healthy people, 192 with probable amnestic MCI, and 324 probable AD patients) from a memory clinic were consecutively included in this study and underwent a spectral domain OCT scan (Maestro, Topcon) to assess total macular volume and thickness. Macular width measurements were also taken in several subregions (central, inner, and outer rings) and in layers such as the retinal nerve fiber (RNFL) and ganglion cell (CGL). The study employed a design of high ecological validity, with adjustment by age, education, sex, and OCT image quality. AD, MCI, and control groups did not significantly vary with regard to volume and retinal thickness in different layers. When these groups were compared, multivariate-adjusted analysis disclosed no significant differences in total (p = 0.564), CGL (p = 0.267), RNFL (p = 0.574), and macular thickness and volume (p = 0.380). The only macular regions showing significant differences were the superior (p = 0.040) and nasal (p = 0.040) sectors of the inner macular ring. However, adjustment for multiple comparisons nullified this significance. These results are not supporting existing claims for the usefulness of macular thickness as a biomarker of cognitive impairment in a memory unit. OCT biomarkers for AD should be subject to further longitudinal testing.

Identifiants

DOI: 10.1038/s41598-020-58399-4 PMID: 32005868 PMC: PMC6994670
pubmed: 32005868
doi: 10.1038/s41598-020-58399-4
pii: 10.1038/s41598-020-58399-4
pmc: PMC6994670
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1580

Références

Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273 (2012).
pubmed: 22437338 pmcid: 3331862 doi: 10.1097/NEN.0b013e31824b211b
Morris, J. C. et al. Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. Arch. Neurol. 58, 124–129 (2001).
Bondi, M. W. et al. Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates. J. Alzheimers. Dis. 42, 275–289 (2014).
pubmed: 24844687 pmcid: 4133291 doi: 10.3233/JAD-140276
Petersen, R. C. et al. Mild cognitive impairment: A concept in evolution. J. Intern. Med. 275, 214–228 (2014).
pubmed: 24605806 pmcid: 3967548 doi: 10.1111/joim.12190
Espinosa, A. et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J. Alzheimers. Dis. 34, 769–780 (2013).
pubmed: 23271318 doi: 10.3233/JAD-122002 pmcid: 23271318
Gainotti, G., Quaranta, D., Vita, M. G. & Marra, C. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease. J. Alzheimers. Dis. 38, 481–495 (2014).
pubmed: 24002185 doi: 10.3233/JAD-130881 pmcid: 24002185
Jack, C. R. & Holtzman, D. M. Biomarker modeling of Alzheimer’s disease. Neuron 80, 1347–1358 (2013).
pubmed: 24360540 pmcid: 3928967 doi: 10.1016/j.neuron.2013.12.003
McKhann, G. et al. The diagnosis of Dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers. Dement. 7, 263–269 (2011).
pubmed: 21514250 pmcid: 3312024 doi: 10.1016/j.jalz.2011.03.005
Dubois, B. et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 9, 1118–1127 (2010).
pubmed: 20934914 doi: 10.1016/S1474-4422(10)70223-4 pmcid: 20934914
Engler, H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129, 2856–2866 (2006).
pubmed: 16854944 doi: 10.1093/brain/awl178
Diniz, B. S. O., Pinto, J. A. & Forlenza, O. V. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression ofmild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J. Biol. Psychiatry 9, 172–182 (2008).
pubmed: 17886169 doi: 10.1080/15622970701535502
Puliafito, C. A. et al. Imaging of macular diseases with optical coherence tomography. Ophthalmol. 102, 217–229 (1995).
doi: 10.1016/S0161-6420(95)31032-9
Kromer, R., Serbecic, N., Hausner, L., Froelich, L. & Beutelspacher, S. C. Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer’s disease. Front. Neurol. 4, 203 (2013).
pubmed: 24379800 pmcid: 3864196 doi: 10.3389/fneur.2013.00203
Parisi, V. et al. Correlation between optical coherence tomography, pattern electroretinogram, and visual evoked potentials in openangle glaucoma patients. Ophthalmol. 108, 905–912 (2001).
doi: 10.1016/S0161-6420(00)00644-8
Polo, V. et al. Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer’s disease. Eye 28, 680–690 (2014).
pubmed: 24625377 pmcid: 4058616 doi: 10.1038/eye.2014.51
Garcia-Martin, E. et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson’s disease. Ophthalmol. 119, 2161–2167 (2012).
doi: 10.1016/j.ophtha.2012.05.003
Iseri, P. K., Altinas, Z., Tokay, T. & Yüksel, N. Relationship between Cognitive Impairment and Retinal Morphological and Visual Functional Abnormalities in Alzheimer Disease. J. Neuro-Ophthalmol. 26, 18–24 (2006).
doi: 10.1097/01.wno.0000204645.56873.26
Katz, B. & Rimmer, S. Ophthalmologic manifestations of Alzheimer’s disease. Surv. Ophthalmol. 34, 31–43 (1989).
pubmed: 2678551 doi: 10.1016/0039-6257(89)90127-6
Cogan, D. G. Visual disturbances with focal progressive dementing disease. Am. J. Ophthalmol. 100, 68–72 (1985).
pubmed: 3893141 doi: 10.1016/S0002-9394(14)74985-2 pmcid: 3893141
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T. & DeLong, M. R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122–126 (1981).
pubmed: 7283399 doi: 10.1002/ana.410100203
Berisha, F., Feke, G. T., Trempe, C. L., McMeel, J. W. & Schepens, C. L. Retinal abnormalities in early Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 48, 2285–2289 (2007).
pubmed: 17460292 doi: 10.1167/iovs.06-1029
MacGillivray, T. J. et al. Retinal imaging as a source of biomarkers for diagnosis, characterization and prognosis of chronic illness or long-term conditions. Br. J. Radiol. 87(1040), 20130832 (2014).
pubmed: 24936979 pmcid: 4112401 doi: 10.1259/bjr.20130832
Ikram, M. K., Cheung, C. Y., Wong, T. Y. & Chen, C. P. L. H. Retinal pathology as biomarker for cognitive impairment and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 83, 917–922 (2012).
pubmed: 22733082 doi: 10.1136/jnnp-2011-301628
Hinton, D. R., Sadun, A. A., Blanks, J. C. & Miller, C. A. Optic- nerve degeneration in Alzheimer’s disease. N. Engl. J. Med. 315, 485–487 (1986).
pubmed: 3736630 doi: 10.1056/NEJM198608213150804
Sadun, A. A. & Bassi, C. J. Optic nerve damage in Alzheimer’s disease. Ophthalmol. 97, 9–17 (1990).
doi: 10.1016/S0161-6420(90)32621-0
Davies, D. C., McCoubrie, P., McDonald, B. & Jobst, K. A. Myelinated axon number in the optic nerve is unaffected by Alzheimer’s disease. Br. J. Ophthalmol. 79, 596–600 (1995).
pubmed: 7542917 pmcid: 505173 doi: 10.1136/bjo.79.6.596
Ratchford, J. N. et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurol. 73, 302–308 (2009).
doi: 10.1212/WNL.0b013e3181af78b8
Martinez-Lapiscina, E. H. et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study. Lancet Neurol. 15, 574–584 (2016).
pubmed: 27011339 doi: 10.1016/S1474-4422(16)00068-5
Jentsch, S. et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol. 93, 241–247 (2015).
doi: 10.1111/aos.12609
Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski, J. Q. & Dunaief, J. L. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol. Vis. 9, 184–190 (2003).
pubmed: 12764254 pmcid: 12764254
Ascaso, F. J. et al. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J. Neurol. 8, 1522–1530 (2014).
doi: 10.1007/s00415-014-7374-z
Den Haan, J., Verbraak, F. D., Visser, P. J. & Bouwman, F. H. Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimer’s Dement. Diagnosis. 6, 162–170 (2017).
Coppola, G. et al. Optical Coherence Tomography in Alzheimer’s Disease: A Meta-Analysis. PLoS One 10(8), e0134750, https://doi.org/10.1371/journal.pone.0134750 (2015).
doi: 10.1371/journal.pone.0134750 pubmed: 26252902 pmcid: 4529274
Thomson, K. L., Yeo, J. M., Waddell, B., Cameron, J. R. & Pal, S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers. Dement. Diagnosis, Assess. Dis. Monit. 1, 136–143 (2015).
Larrosa, J. M. et al. Potential new diagnostic tool for Alzheimer’s disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 5, 3043–3051 (2014).
doi: 10.1167/iovs.13-13629
Garcia-Martin, E. et al. Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. Acta Ophthalmol. 6, 454–459 (2016).
doi: 10.1111/aos.12977
Den Haan, J. et al. Retinal Imaging Retinal thickness as a potential biomarker in patients with amyloid-proven early-and late-onset Alzheimer’s disease. Alzheimer’s Dement. Diagnosis 11, 463–471 (2019).
Poroy, C. & Yücel, A. Â. Optical Coherence Tomography: Is Really a New Biomarker for Alzheimer’s Disease? Ann. Indian. Acad. Neurol. 2, 119–125 (2018).
doi: 10.4103/aian.AIAN_368_17
Kromer, R. et al. Detection of Retinal Nerve Fiber Layer Defects in Alzheimer’s Disease Using SD-OCT. Front. psychiatry 5, 22 (2014).
pubmed: 24616709 pmcid: 3934110 doi: 10.3389/fpsyt.2014.00022
Sánchez, D. et al. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease. Sci. Rep. 8, 16345 (2018).
pubmed: 30397251 pmcid: 6218495 doi: 10.1038/s41598-018-34577-3
Marquié, M. et al. Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Sci. Rep. 9, 8698 (2019).
pubmed: 31213626 pmcid: 6581941 doi: 10.1038/s41598-019-45055-9
Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmol. 98, 786–806 (1991).
doi: 10.1016/S0161-6420(13)38012-9
Lad, E. M. et al. Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer’s disease. PLoS One 13(2), e0192646 (2018).
pubmed: 29420642 pmcid: 5805310 doi: 10.1371/journal.pone.0192646
Knoll, B. et al. Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: Case-control study and meta-analysis. Alzheimers. Dement. 4, 85–93 (2016).
Salobrar-Garcia, E. et al. Analysis of Retinal Peripapillary Segmentation in Early Alzheimer’s Disease Patients. Biomed. Res. Int. 2015, 636548 (2015).
pubmed: 26557684 pmcid: 4628738 doi: 10.1155/2015/636548
Lijmer, J. G. et al. Empirical evidence of design-related bias in studies of diagnostic tests. J.A.M.A. 282, 1061–1066 (1999).
pubmed: 10493205 doi: 10.1001/jama.282.11.1061 pmcid: 10493205
Whiting, P. et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann. Intern. Med. 140, 189–202 (2004).
pubmed: 14757617 doi: 10.7326/0003-4819-140-3-200402030-00010 pmcid: 14757617
Bernick, C., Cummings, J., Raman, R., Sun, X. & Aisen, P. Age and rate of cognitive decline in Alzheimer disease: implications forclinical trials. Arch. Neurol. 69, 901–905 (2012).
pubmed: 22431834 doi: 10.1001/archneurol.2011.3758 pmcid: 22431834
Ghiso, J., Doudevski, I., Ritch, R. & Rostagno, A. Alzheimer’s disease and glaucoma: mechanistic similarities and differences. J. Glaucoma 22, S36–S38 (2013).
pubmed: 23733125 pmcid: 3955061 doi: 10.1097/IJG.0b013e3182934af6
Budenz, D. L. et al. Determinants of normal retinal nerve fiber layer thickness measured by Stratus OCT. Ophthalmol. 114, 1046–1052 (2007).
doi: 10.1016/j.ophtha.2006.08.046
Marziani, E. et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer’s disease using spectral domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 54, 5953–5958 (2013).
pubmed: 23920375 doi: 10.1167/iovs.13-12046
Cheung, C. Y. L. et al. Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimers. Dement. 10, 135–142 (2014).
pubmed: 24439169 doi: 10.1016/j.jalz.2013.06.009
de Jong, F. J. et al. Retinal vascular caliber and risk of dementia: the Rotterdam study. Neurol. 76, 816–821 (2011).
doi: 10.1212/WNL.0b013e31820e7baa
Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. J.A.M.A. 313, 1939–1349 (2015).
pubmed: 25988463 doi: 10.1001/jama.2015.4669
Bouwman, F. H. et al. CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol. Aging 30, 1895–1901 (2009).
pubmed: 18403055 doi: 10.1016/j.neurobiolaging.2008.02.007
Alegret, M. et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J. Clin. Exp. Neuropsychol. 34, 209–202 (2012).
pubmed: 22149440 doi: 10.1080/13803395.2011.630652
Alegret, M. et al. Cut-off scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual adults older than 44 years old. PLoS One 8, 1–8 (2013).
doi: 10.1371/journal.pone.0076436
Boada, M. et al. Design of a comprehensive Alzheimer’s disease clinic and research center in Spain to meet critical patient and family needs. Alzheimers. Dement. 10, 409–415 (2014).
pubmed: 24035148 doi: 10.1016/j.jalz.2013.03.006
Yang, Q. et al. Automated layer segmentation of macular OCT images using dual-scale gradient information. Opt. Express 18, 21293–21307 (2010).
pubmed: 20941025 pmcid: 3101081 doi: 10.1364/OE.18.021293
Nagarkatti-Gude, N. et al. Optical Coherence Tomography Segmentation Errors of the Retinal Nerve Fiber Layer Persist Over Time. J. Glaucoma. 28, 368–374 (2019).
pubmed: 30855415 doi: 10.1097/IJG.0000000000001222
Petersen, R. C. et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol. 56, 1133–1142 (2001).
doi: 10.1212/WNL.56.9.1133
Lopez, O. L. et al. Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Arch. Neurol. 60, 1385 (2003).
pubmed: 14568808 doi: 10.1001/archneur.60.10.1385
McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurol. 34, 939–944 (1984).
doi: 10.1212/WNL.34.7.939
Cruz-Herranz, A. et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurol. 86, 2303–2309 (2016).
doi: 10.1212/WNL.0000000000002774

Auteurs

Domingo Sánchez (D)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain. dsanchez@fundacioace.com.
ORCID: 0000-0001-5089-3247

Miguel Castilla-Marti (M)

Clínica Oftalmológica Dr. Castilla, Barcelona, Spain.
Department of Ophthalmology, Hospital de l'Esperança, Parc de Salut Mar, Barcelona, Spain.
ORCID: 0000-0003-1886-3536

Marta Marquié (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0002-0660-0950

Sergi Valero (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Sonia Moreno-Grau (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Octavio Rodríguez-Gómez (O)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Albert Piferrer (A)

Topcon España Clinical Affairs, Sant Just Desvern, Spain.

Gabriel Martínez (G)

Faculty of Medicine and Dentistry, Universidad de Antofagasta, Antofagasta, Chile.
Iberoamerican Cochrane Centre, Barcelona, Spain.

Joan Martínez (J)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Itziar De Rojas (I)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
ORCID: 0000-0002-2148-381X

Isabel Hernández (I)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Carla Abdelnour (C)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Maitée Rosende-Roca (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Liliana Vargas (L)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Ana Mauleón (A)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Silvia Gil (S)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Montserrat Alegret (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Gemma Ortega (G)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Ana Espinosa (A)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Alba Pérez-Cordón (A)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Ángela Sanabria (Á)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Natalia Roberto (N)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.

Andreea Ciudin (A)

Diabetes and Metabolism Research Unit and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólica Asociada (CIBERDEM), Vall d'Hebron Research Institute, Barcelona, Spain.

Rafael Simó (R)

Diabetes and Metabolism Research Unit and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólica Asociada (CIBERDEM), Vall d'Hebron Research Institute, Barcelona, Spain.

Cristina Hernández (C)

Diabetes and Metabolism Research Unit and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólica Asociada (CIBERDEM), Vall d'Hebron Research Institute, Barcelona, Spain.

Lluís Tárraga (L)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Mercè Boada (M)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Agustín Ruiz (A)

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0003-2633-2495

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Evaluation of macular thickness and volume...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Evaluation of macular thickness and volume...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Evaluation of macular thickness and volume...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Evaluation of macular thickness and volume...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Evaluation of macular thickness and volume...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evaluation of macular thickness and volume...
questionsmedicales.fr › Organes des sens › Oeil › Rétine › Macula › Evaluation of macular thickness and volume...
questionsmedicales.fr › Techniques d'investigation › Imagerie optique › Tomographie optique › Tomographie par cohérence optique › Evaluation of macular thickness and volume...